We recently showed that the novel FABP5 inhibitor ART26.12 prevented and treated oxaliplatin‐induced peripheral neuropathy (OIPN) in a CB1‐dependent manner, with involvement from TRPV1, CB2 and peroxisome proliferator‐activated receptor alpha (Warren et al., 2024). This evidence concerns the gene FABP5 and peripheral neuropathy.